Eve Harris, who recently took a fulltime job as a patient navigator at UCSF, published her “coming out” piece, as she calls it - “Skin in the game.” She writes that she intends to use her blog to build on some of the themes foreshadowed in this piece: “cancer-related lifestyle consequences, screening harms and benefits, shared decision making, treatment of DCIS, health literacy, patient experience and more.”
“A Check on Physicals,” by Jane Brody of the New York Times, including an examination of the “sales pitch for the Princeton Longevity Center’s “comprehensive exam” promises, for $5,300, to take “your health beyond the annual physical.”
When the Cancer Research UK charity posted this photo on its Facebook page, it caused quite a kerfuffle in some circles.
The Facebook page itself lit up with comments, some calling it “insulting…naive…arrogant…ignorant…terrible…at best badly expressed and at worst dangerous” and much more. Others wrote their support. Science writer Ed Yong, a former public information officer for Cancer Research UK, tweeted that it was “Just *astonishing* arrogance in the face of complex biology.” Other science journalists tweeted that it was “actually cruel…astonishing but unsurprising.” The charity later blogged an apology of sorts – “A Future Free From the Fear of Cancer? Yes, But…“- which didn’t satisfy many observers.
And, after all that, we end with some humor:
The Daily Show’s “medical correspondent, Dr. Aasif Mandvi” on the “lie-enhancing drugs – Fibodrine, Deceptafran, Fraudulax, Perjursil, Defamatol… ” that might explain Lance Armstrong’s behavior.
This story describes a new way to calculate mortality risk from a treadmill test as a silver bullet that can save lives in minutes at no cost and no risk. A competing LA Times story on the same study was better.
This story is about access to a marijuana-based extract called cannabidiol oil. But we’re not necessarily talking about something that’s synthesized at the local dispensary. This is a pharmaceutical cannabidiol product that can be obtained with FDA permission by physicians through an Investigational New Drug application. The story should have made this clear.